JP5628145B2 - 新規チロシンキナーゼ阻害剤 - Google Patents

新規チロシンキナーゼ阻害剤 Download PDF

Info

Publication number
JP5628145B2
JP5628145B2 JP2011500801A JP2011500801A JP5628145B2 JP 5628145 B2 JP5628145 B2 JP 5628145B2 JP 2011500801 A JP2011500801 A JP 2011500801A JP 2011500801 A JP2011500801 A JP 2011500801A JP 5628145 B2 JP5628145 B2 JP 5628145B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
methyl
alk
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011500801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515397A5 (OSRAM
JP2011515397A (ja
Inventor
グレガー，ヴラド・エドワード
リュー，ヤフア
アニキン，アレクセイ
ミケル，チャールズ
マクグラス，ダグラス・エリック
ヴァヴィララ，ゴヴェルダン・レディ
ピッケンズ，ジェーソン・シー
カダシュキン，アレクサンダー
ジャン，ルヨン
シルヴァジ，モハン・サンサナム
ゾズルヤ，セルゲイ
ヴァイラゴウンダー，ラネンドラン
ジュウ，トン
チュチョロウスキ，アレクサンダー
ヤン，チェン
カサノヴ，アリシャー
Original Assignee
ケムブリッジ・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケムブリッジ・コーポレーション filed Critical ケムブリッジ・コーポレーション
Publication of JP2011515397A publication Critical patent/JP2011515397A/ja
Publication of JP2011515397A5 publication Critical patent/JP2011515397A5/ja
Application granted granted Critical
Publication of JP5628145B2 publication Critical patent/JP5628145B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2011500801A 2008-03-19 2009-03-18 新規チロシンキナーゼ阻害剤 Expired - Fee Related JP5628145B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3803208P 2008-03-19 2008-03-19
US61/038,032 2008-03-19
PCT/US2009/001691 WO2009117097A1 (en) 2008-03-19 2009-03-18 Novel tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013006922A Division JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2011515397A JP2011515397A (ja) 2011-05-19
JP2011515397A5 JP2011515397A5 (OSRAM) 2012-05-10
JP5628145B2 true JP5628145B2 (ja) 2014-11-19

Family

ID=40814009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011500801A Expired - Fee Related JP5628145B2 (ja) 2008-03-19 2009-03-18 新規チロシンキナーゼ阻害剤
JP2013006922A Pending JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013006922A Pending JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Country Status (9)

Country Link
US (1) US8815906B2 (OSRAM)
EP (2) EP2966076A1 (OSRAM)
JP (2) JP5628145B2 (OSRAM)
CN (1) CN102036990B (OSRAM)
AU (1) AU2009226153B2 (OSRAM)
CA (1) CA2718872C (OSRAM)
DK (1) DK2262807T3 (OSRAM)
MX (1) MX2010010272A (OSRAM)
WO (1) WO2009117097A1 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249147B2 (en) * 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
AU2009226153B2 (en) * 2008-03-19 2014-02-20 Chembridge Corporation Novel tyrosine kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
WO2012037155A2 (en) 2010-09-13 2012-03-22 Gtx, Inc. Tyrosine kinase inhibitors
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
JP2014533286A (ja) * 2011-11-14 2014-12-11 テサロ， インコーポレイテッド 特定のチロシンキナーゼの調節
AU2013253541A1 (en) 2012-04-24 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
TW201348187A (zh) 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 苯甲醯胺衍生物
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015060373A1 (ja) 2013-10-23 2015-04-30 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
CA2938818C (en) * 2014-02-04 2023-03-07 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
JP2017511369A (ja) * 2014-04-17 2017-04-20 アムジエン・インコーポレーテツド Ｃ−ｍｅｔ阻害剤の多形体及び共結晶
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
SG11201706901TA (en) * 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
MX372914B (es) 2015-06-16 2020-04-27 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN116096715A (zh) 2020-07-06 2023-05-09 泰科根公司 用于精神障碍或精神增强的有益苯并噻吩组合物
TW202220965A (zh) 2020-08-06 2022-06-01 美商塔朵根公司 用於心理疾患或心理增強之２－胺基茚滿化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0600830A1 (de) * 1992-11-27 1994-06-08 Ciba-Geigy Ag Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
AP2005003451A0 (en) 2003-04-28 2005-12-31 Tibotec Pharm Ltd HIV integrase inhibitors.
AU2004259012C1 (en) * 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN101160312A (zh) * 2005-04-14 2008-04-09 霍夫曼-拉罗奇有限公司 三环吡咯衍生物、它们的制备和作为药剂的应用
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
US20080062003A1 (en) * 2006-08-07 2008-03-13 Christian Paetz Wireless controllable power control device molded into a power cable
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
AU2009226153B2 (en) * 2008-03-19 2014-02-20 Chembridge Corporation Novel tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN102036990A (zh) 2011-04-27
AU2009226153A1 (en) 2009-09-24
WO2009117097A1 (en) 2009-09-24
EP2262807B1 (en) 2015-08-12
AU2009226153B2 (en) 2014-02-20
JP2013082744A (ja) 2013-05-09
EP2966076A1 (en) 2016-01-13
DK2262807T3 (en) 2015-11-30
CA2718872C (en) 2016-09-13
EP2262807A1 (en) 2010-12-22
CN102036990B (zh) 2015-09-30
MX2010010272A (es) 2011-05-25
CA2718872A1 (en) 2009-09-24
US20130053376A1 (en) 2013-02-28
US8815906B2 (en) 2014-08-26
JP2011515397A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
JP5628145B2 (ja) 新規チロシンキナーゼ阻害剤
EP3931188B1 (en) New isoindolinone substituted indoles and derivatives as ras inhibitors
JP6586104B2 (ja) ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
KR101483215B1 (ko) 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
JP6819585B2 (ja) Ｂｒｋ阻害化合物
JP6355648B2 (ja) Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
TW201930292A (zh) 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
WO2015081813A1 (zh) 具有alk抑制活性的化合物及其制备与用途
JP6403761B2 (ja) ピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
CN104902894A (zh) 具有电压门控性钠通道选择性活性的苯并噁唑啉酮化合物
CN103370314A (zh) 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物
RS52313B (sr) Jedinjenja za inhibiciju napredovanja mitoze
CN107635986A (zh) 取代的喹喔啉衍生物
CN105452257A (zh) 新型稠合嘧啶化合物或其盐
JP4937881B2 (ja) アズレン化合物
US9249147B2 (en) Tyrosine kinase inhibitors
CN119013017A (zh) 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用于治疗癌症的药物组合物
HK40053745B (zh) Sting激动性化合物
HK40009843A (en) Fgfr inhibitor and application thereof
HK1163089A1 (zh) 做为蛋白激酶抑制剂的稠合多环化合物
HK1163089B (en) Fused multicyclic compounds as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140827

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141001

R150 Certificate of patent or registration of utility model

Ref document number: 5628145

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees